Skip to main content

There has been a lapse in appropriated federal funds as of October 1, 2025. Grants.gov and Simpler.Grants.gov will still be available, but service may be delayed with reduced Federal support staff presence.

For those programs affected by the funding lapse, the Grants.gov and Simpler.Grants.gov systems will accept and store applications until such time as the responsible awarding agency has the authority and funding to return to normal business operations.

This site is a work in progress, with new features and updates based on your feedback.

Search for grants here. To use more advanced features or to apply, go to Grants.gov.

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)

Agency: National Institutes of Health

Assistance Listings: 93.394 -- Cancer Detection and Diagnosis Research

Last Updated: October 15, 2024

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

Eligibility

Eligible applicants

Government

  • City or township governments
  • State governments
  • Public and Indian housing authorities
  • Special district governments
  • County governments
  • Federally recognized Native American tribal governments

Education

  • Private institutions of higher education
  • Public and state institutions of higher education
  • Independent school districts

Business

  • For-profit organizations other than small businesses
  • Small businesses

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education without 501(c)(3)
  • Nonprofits non-higher education with 501(c)(3)

Miscellaneous

  • Other

Additional information

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Grantor contact information

Description

NIH Grants Information grantsinfo@nih.gov

Email

See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

grantsinfo@nih.gov

Documents

File nameDescriptionLast updated
PAR-23-314-Full-Announcement.html
PAR-23-314 Full Announcement Text
Nov 1, 2023 05:59 PM UTC

Link to additional information

https://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html

Closing: October 15, 2025

Application process

This site is a work in progress. Go to www.grants.gov to apply, track application status, and subscribe to updates.

Award

$--

Program Funding

--

Expected awards

$--

Award Minimum

$250,000

Award Maximum

Funding opportunity number:

PAR-23-314

Cost sharing or matching requirement:

No

Funding instrument type:

Cooperative agreement

Opportunity Category:

Discretionary

Opportunity Category Explanation:

--

Category of Funding Activity:

Education

Health

Category Explanation:

--

History

Version:

2

Posted date:

October 31, 2023

Archive date:

November 14, 2025

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov